Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.

MLA

Mones, Jodi V., et al. “Dose-Attenuated Radioimmunotherapy with Tositumomab and Iodine 131 Tositumomab in Patients with Recurrent Non-Hodgkin’s Lymphoma (NHL) and Extensive Bone Marrow Involvement.” Leukemia & Lymphoma, vol. 48, no. 2, Feb. 2007, pp. 342–48. EBSCOhost, https://doi.org/10.1080/10428190601059720.

APA

Mones, J. V., Coleman, M., Kostakoglu, L., Furman, R. R., Chadburn, A., Shore, T. B., Muss, D., Stewart, P., Kroll, S., Vallabhajosula, S., Goldsmith, S. J., & Leonard, J. P. (2007). Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin’s lymphoma (NHL) and extensive bone marrow involvement. Leukemia & Lymphoma, 48(2), 342–348. https://doi.org/10.1080/10428190601059720

Chicago

Mones, Jodi V., Morton Coleman, Lale Kostakoglu, Richard R. Furman, Amy Chadburn, Tsiporah B. Shore, Daniel Muss, et al. 2007. “Dose-Attenuated Radioimmunotherapy with Tositumomab and Iodine 131 Tositumomab in Patients with Recurrent Non-Hodgkin’s Lymphoma (NHL) and Extensive Bone Marrow Involvement.” Leukemia & Lymphoma 48 (2): 342–48. doi:10.1080/10428190601059720.